Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1100 of 2026 entries
View as:

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

Phase: N/A Priority: Normal
NCT ID: NCT03684044 Org: User:
Start: 01/08/19 End: 03/16/20 Due: 03/16/21

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Phase: N/A Priority: Normal
NCT ID: NCT02627274 Org: User:
Start: 12/07/15 End: 11/10/22 Due: 11/10/23

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

Phase: N/A Priority: Normal
NCT ID: NCT00233883 Org: User:
Start: 08/31/05 End: 07/31/06 Due: 07/31/07

A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.

Phase: N/A Priority: Normal
NCT ID: NCT01290718 Org: User:
Start: 12/31/11 End: 12/31/12 Due: 12/31/13

A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01928615 Org: User:
Start: 09/30/13 End: 10/31/13 Due: 10/31/14

A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT00559637 Org: User:
Start: 01/31/08 End: 06/30/10 Due: 06/30/11

A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01705717 Org: User:
Start: 06/01/11 End: 05/01/12 Due: 05/01/13

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Phase: N/A Priority: Normal
NCT ID: NCT01332968 Org: User:
Start: 07/06/11 End: 07/30/21 Due: 07/30/22

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Phase: N/A Priority: Normal
NCT ID: NCT03271554 Org: User:
Start: 11/09/17 End: 05/28/21 Due: 05/28/22

STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients

Phase: N/A Priority: Normal
NCT ID: NCT00642850 Org: User:
Start: 11/30/07 End: 07/31/09 Due: 07/31/10

Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT02251860 Org: User:
Start: 05/20/14 End: 07/23/20 Due: 07/23/21

A Study of RO5185426 in Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01248936 Org: User:
Start: 12/31/10 End: 10/31/11 Due: 10/31/12

Expanded Access to RXDX-105 for Cancers With RET Alterations

Phase: N/A Priority: Normal
NCT ID: NCT03052569 Org: User:
Start: - End: - Due: -

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00448279 Org: User:
Start: 04/30/07 End: 09/30/10 Due: 09/30/11

A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02716792 Org: User:
Start: 01/31/06 End: 08/31/08 Due: 08/31/09

Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency of Depression in Rheumatoid Arthritis (RA) Participants

Phase: N/A Priority: Normal
NCT ID: NCT02485483 Org: User:
Start: 11/30/12 End: 07/31/15 Due: 07/31/16

Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial

Phase: N/A Priority: Normal
NCT ID: NCT00468702 Org: User:
Start: 09/30/07 End: - Due: -

A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01418989 Org: User:
Start: 07/31/11 End: 11/30/11 Due: 11/30/12

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Phase: N/A Priority: Normal
NCT ID: NCT01691846 Org: User:
Start: 10/31/12 End: 09/30/13 Due: 09/30/14

An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids

Phase: N/A Priority: Normal
NCT ID: NCT01564901 Org: User:
Start: 01/31/12 End: 10/31/12 Due: 10/31/13

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05861999 Org: User:
Start: 08/14/24 End: 03/31/28 Due: 03/31/29

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04644315 Org: User:
Start: 05/24/21 End: 05/16/22 Due: 05/16/23

PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00774241 Org: User:
Start: 01/31/10 End: 11/30/13 Due: 11/30/14

A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00518011 Org: User:
Start: 08/31/07 End: 02/28/09 Due: 02/28/10

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04300647 Org: User:
Start: 06/30/20 End: 02/24/25 Due: 02/24/26